Micke O, Prott F J, Schäfer U, Tangerding S, Pötter R, Willich N
Department of Radiotherapy and Radiation Oncology, University of Münster, Münster, Germany.
Anticancer Res. 2000 Nov-Dec;20(6D):5113-5.
The impact of Squamous cell carcinoma antigen (SCC) in the follow-up of patients with cervical cancer treated with radiotherapy was evaluated. 72 patients with a histologically proven squamous cell carcinoma of the uterine cervix were treated at the Department of Radiotherapy and Radiation Ocology, Munster, Germany. The pretherapeutic serum level of SCC was elevated in 60% of patients (cut-off-level: 2.5 ng/ml). The median serum level correlated with the tumor stage. After the end of radiation treatment, 98% of patients in complete remission and 87% of patients in partial remission had a serum level below the cut-off. In the case of recurrent disease, 71% of patients had a significant increase of SCC serum levels before clinical manifestation of relapse. The leading time ranged between one and 16 months (median: 3.1 months). In conclusion, SCC is a useful tumor marker in the follow-up of patients with squamous cell carcinoma of the uterine cervix.
评估了鳞状细胞癌抗原（SCC）在接受放疗的宫颈癌患者随访中的影响。德国明斯特放射治疗与放射肿瘤学系对72例经组织学证实为子宫颈鳞状细胞癌的患者进行了治疗。60%的患者治疗前血清SCC水平升高（临界值：2.5 ng/ml）。血清水平中位数与肿瘤分期相关。放射治疗结束后，完全缓解的患者中有98%以及部分缓解的患者中有87%的血清水平低于临界值。在疾病复发的情况下，71%的患者在复发临床表现出现前SCC血清水平显著升高。领先时间在1至16个月之间（中位数：3.1个月）。总之，SCC是子宫颈鳞状细胞癌患者随访中一种有用的肿瘤标志物。
